Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

FitFlow vs MyStart Health

FitFlow
Graded #155

Higher grade

vs+0.7000000000000028
MyStart Health
Graded #168

Lower grade

The verdict

FitFlow takes it — 67.8/100 to 67.1/100, but only just.

FitFlow grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. FitFlow (FitFlow Health) is a 100% online compounded telehealth platform for GLP-1 weight loss - compounded semaglutide (=Wegovy) and tirzepatide (=Mounjaro). MyStart Health is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueFitFlow +10
58
48
Dose & formulationMyStart Health +6
77
83
Clinical oversightFitFlow +1
85
84
Labs & monitoringMyStart Health +11
55
66
FulfillmentFitFlow +3
81
78
Contract termsFitFlow +6
37
31
FitFlow · left barMyStart Health · right bar

The numbers

MetricFitFlowMyStart Health
WeighScore67.8/10067.1/100
GradeCC
Scorecard rank#155#168
Semaglutide$175/mo (compounded)$299/mo (all doses, compounded)
Tirzepatide$235/mo (compounded)$299/mo (all doses, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyYes
FitFlow

Graded #155 · C

Strengths

  • Compounded semaglutide (=Wegovy) and tirzepatide (=Mounjaro); month-to-month from $175/$235, or as low as $99/$125 on annual prepay
  • 100% online 4-step process; board-certified provider review in 24-48 hours, with unlimited messaging and dose adjustments
  • Free nationwide shipping (discreet, 5-7 days) from US-licensed compounding pharmacies
  • FSA/HSA eligible with financing (Affirm, Klarna, Afterpay); month-to-month or prepay plans, cancel anytime
  • Transparent 'no hidden fees' pricing; 6,000+ members; same-platform add-ons (NAD+, sermorelin, MIC+B12, glutathione, hair, sexual health)

Where it loses points

  • Headline '$99/$125 a month' requires a full year prepaid upfront ($1,188 / $1,500); true month-to-month is $175 / $235
  • Compounded medications are not FDA-approved - not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • The compounding pharmacy partner is not named ('US-licensed / FDA-regulated pharmacies' only)
  • State-availability list is not published (free nationwide shipping advertised, but no explicit state list)
  • No LegitScript certification displayed
MyStart Health

Graded #168 · C

Strengths

  • Price Lock Guarantee — your $299 base rate doesn't rise as your dose escalates
  • Fast onboarding: roughly 5-minute intake, 24-hour prescription turnaround, 2–4 day shipping
  • 24/7 care team access with unlimited clinician messaging included
  • LegitScript certified
  • Clear Section 503A compounding disclosure on every landing page

Where it loses points

  • Not BBB accredited — C+ rating with 10 complaints, mostly shipping delays and support access
  • Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro
  • Markets oral tirzepatide, but no FDA-approved oral tirzepatide exists
  • Very new company (incorporated May 2024) with a limited track record
  • Pharmacy partners not named, so 503A compliance can't be independently verified

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard